Synapse - Andrew Laccetti

Results (26)

Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results

Meeting Abstract

Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Nowfar, S.; Einstein, D. J.; Martin, B.; Adorjan, P.; Dissanayake, M.; Verholen, F.; Gao, X.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer

Meeting Abstract

Wax, I.; Markus, A.; Carlson, A.; Scott, J.; Jones, L. W.; Laccetti, A. L.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 1B trial of masofaniten (EPI-7386) in patients with metastatic castration-resistant prostate cancer (MCRPC)

Meeting Abstract

Laccetti, A.; Iannotti, N.; Pachynski, R.; Carthon, B.; Chi, K. N.; Smith, M.; Saad, F.; Pili, R.; Tu, W.; Kwan, E. M.; more...
Urologic Oncology: Seminars and Original Investigations (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects

Meeting Abstract

Kyriakopoulos, C.; Chatta, G.; Laccetti, A. L.; Iannotti, N.; Sokolova, A. O.; Hotte, S. J.; Tutrone, R.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)

Meeting Abstract

Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design

Meeting Abstract

Kyriakopoulos, C.; Chatta, G. S.; Laccetti, A. L.; Iannotti, N.; Sokolova, A.; Hotte, S. J.; Tutrone, R. F.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)

Meeting Abstract

Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)